Nurix Therapeutics Inc (NRIX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Aug 31 2026 to Aug 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Nurix Therapeutics Inc   (NASDAQ: NRIX)


Nurix Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nurix Therapeutics Inc's ROI in the third quarter of 2026?
Nurix Therapeutics Inc achieved a return on average invested assets (ROI) of 44.12 % in its third quarter of 2026 a new company high.

ROI has improved compared to -66.63% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector Nurix Therapeutics Inc achieved the highest return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 3795 to 3808.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Aug 31 2026)
III. Quarter		 (May 31 2026)
II. Quarter		 (Feb 28 2026)
I. Quarter		 (Nov 30 2025)
IV. Quarter		 (Aug 31 2025)
III. Quarter
Y / Y Investment Change TTM 30.13 % 0.36 % 7.44 % 25.76 % 52.05 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1,065 464 544 602 440
Return On Investment (TTM) 44.12 % -66.63 % -56.2 % -50.79 % -47.66 %
NRIX's Overall Ranking # 3808 # 3795 # 65 # 150 # 54
Seq. Investment Change TTM 30.47 % -2.49 % 0.91 % 1.37 % 0.63 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 295 -341 -295 -264 -245

NRIX Company Profile >> Back to NRIX Roi Comparisons >> See Annual NRIX Return On Investment



Return On Investment NRIX's Ranking
Within: No.
Industry # 1
Sector # 1
Overall # 3808

Return On Investment Statistics
High Average Low
44.12 %
-39.1 %
-66.63 %
(Aug 31 2026)   (May 31 2026)



  News about Nurix Therapeutics Inc Return on Investment ROI

Nurix Therapeutics Charts Ambitious Path Amid Financial Challenges and Promising Pipeline

January 13, 2025

In a significant strategic update, Nurix Therapeutics Inc. has laid out its ambitious goals for 2025, focusing on advancing its robust pipeline targeted at revolutionizing treatment for cancer and autoimmune diseases. One of the highlights of this plan includes the initiation of a suite of clinical trials aimed at supporting the global registration of NX-5948, a therapeutic candidate positioned to tackle chronic lymphocytic leukemia (CLL). This decision reflects the company s commitment to progressing potentially transformative treatments even as it navigates substantial financial headwinds.Despite these substantial efforts to innovate in the biotech arena, Nurix’s financial results tell a contrasting story. For the twelve months ending in the third quarter of 2024, Nurix recorded a staggering net loss of $177 million. Such figures have underscored the high-risk, high-reward nature of the biotech sector, which often sees companies pouring capital into research and development with hopes of significant future returns. As a result of this loss, the company posted a negative return on investment (ROI) of -52.39%, highlighting the challenge of converting research ambitions into profitable outcomes.

Nurix Therapeutics Faces Financial Challenges Amid Advances in Targeted Protein Modulation for Cancer and Autoimmune Diseases

January 8, 2024



Nurix Therapeutics, a biopharmaceutical company focused on targeted protein modulation for the treatment of cancer and autoimmune diseases, has recently outlined its 2024 strategic priorities. The company plans to advance its pipeline and prioritize the enrollment acceleration of NX-5948 for leukemia and lymphoma based on positive Phase 1 data. However, behind these ambitious goals, Nurix faces significant financial challenges, as it reported a cumulative net loss of $-149 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -50.56%.
Nurix s Strategic Priorities and Promising Developments:
Nurix Therapeutics has made significant strides in the field of targeted protein modulation, a promising approach to treat cancer and autoimmune diseases. The company s decision to prioritize the enrollment acceleration of NX-5948 in leukemia and lymphoma is supported by the positive Phase 1 data presented at the American Society of Hematology. This indicates promising therapeutic potential in these challenging diseases.





Financial Statements
Nurix Therapeutics Inc's III. Quarter Investments $ 1,065 Millions NRIX's Balance sheet
Nurix Therapeutics Inc's III. Quarter Income $ 550 Millions Quarterly NRIX's Income Statement
NRIX's Income by Division See NRIX's Income by Division


NRIX Annual Return On Investment (Nov 30 2025)
2025		 (Nov 30 2024)
2024		 (Nov 30 2023)
2023		 (Nov 30 2022)
2022		 (Nov 30 2021)
2021
Total Investments in Millions 602 573 269 346 411
Y / Y Investment Growth 4.91 % 113.48 % -22.38 % -15.69 % 16.69 %
Net Income in Millions -264 -194 -144 -180 -117
Y / Y Net Income Growth - - - - -
Annual Return On Investment -43.95 % -33.75 % -53.58 % -52.11 % -28.55 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NRIX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NRIX's Competitors
Subscribers only: Roi for Nurix Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for NRIX's Customers

Other Ratios
NRIX's Roa NRIX's Inventory Turnover Ratio NRIX's Growth Rates NRIX's Dividend Statistics
NRIX's Profitability Ratios NRIX's Asset Turnover Ratio NRIX's Dividend Growth
NRIX's Roe NRIX's Valuation Ratios NRIX's Financial Strength Ratios NRIX's Dividend Payout Ratio



Companies with similar Return On Investment at Aug 31 2026, within Healthcare Sector ROI
Medpace Holdings Inc   49.54 %
Nurix Therapeutics Inc   44.12 %
Intuitive Surgical Inc   16.26 %
3m Company  13.24 %
Johnson and Johnson  10.53 %

Date modified: 2026-10-14T16:57:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.